Phase 2 Pancreatic Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged between 18 and 75 years old
• People who have been diagnosed with pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer), confirmed through a tissue or cell sample — a tissue sample is preferred
• People whose cancer has been assessed by the trial doctor as unable to be removed by surgery, based on established medical guidelines
• People whose total bilirubin (a substance measured in blood) is at or below 2 mg/dL — people with a bile duct stent may still be considered if this level is met and there is no bile duct infection after stent placement
• People who have not previously received any treatment for pancreatic cancer, including chemotherapy, radiation therapy, or surgery
• People who have at least one tumour that can be measured on scans, a good general health status score (assessed within 28 days before starting the trial), and blood, liver, kidney, clotting, and heart function results that fall within the ranges required by the trial
• People who are willing to use contraception from the first dose until 3 months after the last dose of the study drug — this applies to men and to women who are able to become pregnant

Who may not be able to join:

• People whose cancer has spread to distant parts of the body — if scans raise concern about spread to the lining of the abdomen or fluid in the abdomen, further confirmation through a tissue or cell sample (such as via keyhole surgery) would be required
• People who have a medical reason that would prevent pancreatic surgery
• People who have a known active autoimmune disease (a condition where the immune system attacks the body)
• People who are taking corticosteroid medicines such as prednisone at doses above 10 mg per day, or who have taken immune-suppressing medicines within the 14 days before starting the trial
• People who have received a cancer vaccine or certain immune-stimulating treatments (such as interferon, interleukin, thymosin, or immune cell therapy) within 1 month before starting the trial
• People who are currently taking part in another clinical trial, or who received a drug from another clinical trial within the 4 weeks before starting this trial
• People who have another cancer that currently requires treatment
• People who have a significant history of heart or cardiovascular disease
• People who have previously had an organ transplant or a stem cell transplant from a donor
• People who test positive for HIV
• People with active hepatitis B or active hepatitis C (based on specific blood test results) that requires antiviral treatment
• People who have a known allergy or sensitivity to monoclonal antibody medicines
• People who have a known allergic reaction to any of the study chemotherapy drugs: leucovorin, 5-FU, irinotecan, or oxaliplatin
• People with other illnesses or abnormal test results that the trial doctor believes could affect the study results or would not be in the person's best interest (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.